TNFSF10 and cancer: Using a panel of HNSCC cell lines, Ren et al [30] showed that targeting of TRAIL and Smac bypassed NF-κB activation to induce cancer cell death, raising the potential benefit of co-targeting strategies involving TRAIL for treating HNSCC.